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The miniaturized intraoral drug delivery 
system BuccalDose is composed of a 
replaceable cartridge which is worn in 
a removable prosthesis and an external 
base station for telemedical therapy 
monitoring. The system has now been 
tested for the first time with Parkinson’s 
disease (PD) patients. The study evalu-
ated the usability of the entire system, 
the functionality of the telemedical 
transmission path and the functionality 
of the cartridge, which uses an osmotic 
pumping principle to release a liquid 
drug formulation to the buccal mucosa. 
The BuccalDose system was gener-
ally considered to be easy to handle, 
even with movement disorders, up to a 
mild-moderate disease stage. In addi-
tion, the obtained in vivo release rates of 
the cartridges confirmed the previously 
achieved in vitro release behavior.
The BuccalDose system
The drug delivery system BuccalDose 
is worn as a replaceable cartridge in a 
removable intraoral appliance (Fig. 1). 
During the manufacturing process, spe-
cial attention is given to the installation 
procedures of a cartridge carrier into the 
appliance body, as its original functional 
capabilities (i.e. stability, durability, and 
occlusion) must be maintained [1]. 
The replaceable  cartridge is fabri-
cated from biocompatible materials 
with customized assembly & packaging 
technologies [2]. During operation, water 
from saliva in the mouth generates a 
volumetric flow rate across the semi-
permeable membrane of the cartridge 
by dissolving salt. Thereby, a flexible 
barrier membrane is deflected and the 
separately stored drug is ejected (Fig. 2). 
For the phase I clinical evaluation, no 
drug has been used and air was instead 
ejected. In early stages of the disease, 
BuccalDose could administer dopa-
mine agonists such as pramipexole or 
ropinirole [4], while in the later stages 
levodopa derivatives [5] are promising 
drug candidates. 
The current design of the cartridge is in 
principle further miniaturizable as osmotic 
pumps in general [6]. On the other hand, 
the storable amount of active ingredients 
is then also reduced. The entire Buccal-
Dose system is completed by a tele-
medically linked base station, a mobile 
gateway, and an assistive tool (Fig. 3). 
With the assistive tool, PD patients with 
limited motor skills are able to insert 
and remove the magnetically attachable 
cartridge into the prosthesis and into the 
base station, respectively. In addition, the 
assistive tool serves as a storage con-
tainer for the cartridges. The base station 
measures automatically the fill level 
and reads out a RFID minitag when the 
cartridge is inserted [6]. This data is then 
transmitted together with a time stamp 
via ZigBee to a mobile gateway (smart-
phone) and from there via mobile internet 
to a medical service center. The 
released amount of drug as well 
as additional information, such 
as compliance to the therapy 
plan, can be used for therapy 
adjustment.
Clinical trials
The phase I study without 
drug was performed in two 
steps with 4 and 5 patients of 
Hoehn & Yahr stages 1-2 in 
Tel Aviv (IL) and in Palermo (I), 
respectively. In the first step, the patients 
were observed over 1 day in a clinical 
environment, while during the second 
step they evaluated the system over 3 
subsequent days in their home environ-
ment. The serial data transfer from the 
cartridge to the medical service center 
was successful in 71 of 72 performed 
measurements. Thereby, the non-redun-
dant transmission path is able to cache 
and resend data at different times, if the 
connection is interrupted.
The usability of the BuccalDose system 
in daily life was evaluated in relation 
to the disease stage using a patient 
questionnaire. The usability of the 
base station and the assistive tool was 
mainly perceived as easy, while opera-
tion tends to be more difficult in higher 
disease stages. The wearing comfort 
was independent from the disease 
stage and consistently considered to 
be comfortable. However, the removal 
of the cartridge from the prosthesis with 
the assistive tool was difficult for patients 
with more limited motor skills in moder-
ate or advanced disease stages. The 
osmotic pumping principle was charac-
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Fig.1: Intraoral BuccalDose cartridge integrated in a removable 
partial prosthesis.
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terized by the cumulative weight gain of 
each cartridge, which would be similar 
to its cumulative release rate. On aver-
age, the measured cumulative weight 
gain was 1.65 ± 0.3 mg/h in vivo, which 
is comparable to previously obtained 
in vitro results (1.85 ± 0.02 mg/h). 
From the application and hygienic point 
of view, the cartridges should not be 
reused after removal, e.g. during night 
periods. Therefore, the release rates are 
ideally adapted to last for a period of 
one daytime as the cartridge should be 
completely depleted.
Conclusion & Outlook
The idea of the entire system was 
thereby considered by the patients 
as “very good”. The clinical evaluation 
provided important information on the 
necessary functional design features 
that are required for a miniaturized drug 
delivery device operated by patients 
with movement disorders. The pres-
ent version of the system seems to be 
usable up to a mild-moderate disease 
stage in patients with medium to high 
education level. However, in advanced 
PD, intensive training for correct usage 
may be necessary and for PD patients 
with limited cognitive functions it appears 
to be not suitable. 
The next step is the implementation of a 
new and improved version of the Buc-
calDose system which can be handled 
more intuitively with less operation steps, 
i.e. by integration of the mobile gateway 
into the base station.  
In the framework of the EUREKA project 
OPTIMED, a new and miniaturized ver-
sion of the cartridge is being developed 
that can be also worn on the teeth.
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Fig.2: (a) Functional principle of the osmotic drug 
delivery cartridge; *drug chamber was empty for clini-
cal evaluation. (b) Exemplary membrane deflection 
during operation. (c) Integration of the cartridge into 
a splint or into a removable partial prosthesis during 
clinical evaluation.
Fig.3: (a) Telemedically linked base station and assis-
tive tool for use with BuccalDose cartridge.  
(b) Clinical evaluation of the entire BuccalDose system 
by PD patient.
